BIOLIFE SOLUTIONS INC: GLAZER CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Glazer Capital, LLC amended its Schedule 13G filing on BioLife Solutions Inc., disclosing a change in its passive stake in the cell-and-gene-therapy tools maker. The amendment was filed with the SEC under accession number 0001076809-26-000135. Schedule 13G filings are used by investors holding stakes below the 20% threshold or by qualified institutional investors, and amendments typically signal a shift in position size or ownership status. The exact revised share count and percentage were not detailed in the filing headline. Investors will watch for the updated beneficial ownership figures to gauge Glazer's current conviction in BioLife.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Glazer Capital, LLC, BioLife Solutions Inc